Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Gains from Investment Securities (2016 - 2025)

United Therapeutics' Gains from Investment Securities history spans 17 years, with the latest figure at $600000.0 for Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 99.84% year-over-year to $600000.0; the TTM value through Dec 2025 reached $16.6 million, down 95.86%, while the annual FY2025 figure was $16.6 million, 95.86% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was $600000.0 at United Therapeutics, up from -$237.9 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $378.9 million in Q4 2024 and bottomed at -$237.9 million in Q3 2025.
  • The 5-year median for Gains from Investment Securities is $5.1 million (2024), against an average of $35.9 million.
  • The largest annual shift saw Gains from Investment Securities plummeted 5522.73% in 2021 before it soared 5623.91% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at -$119.3 million in 2021, then skyrocketed by 368.48% to $320.3 million in 2022, then crashed by 95.66% to $13.9 million in 2023, then surged by 2625.9% to $378.9 million in 2024, then crashed by 99.84% to $600000.0 in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Gains from Investment Securities are $600000.0 (Q4 2025), -$237.9 million (Q3 2025), and $263.3 million (Q2 2025).